TruSight Sequencing Panels
Sequencing Panels for Translational Research
For cost-effective, streamlined, targeted next-generation sequencing (NGS) of specific genetic diseases or conditions, Illumina offers TruSight sequencing panels. Designed with recognized healthcare experts at leading institutions, TruSight panels comprise oligo probes targeting genes and regions thought to be relevant for particular diseases or conditions.
Each TruSight sequencing panel offers:
- Streamlined Workflow: Pre-designed, expert-selected content and use of proven Illumina NGS technology reduce assay optimization time and risk of manual error.
- Accurate Results: Deep uniform coverage enables highly accurate variant calling suitable for the clinical research laboratory.
- Increased Productivity: Product lot testing, extended shelf life, and single-lot shipments keep your lab running while reducing costs; TruSight One Sequencing Panel is able to replace multiple genetic assays.
TruSight RNA Pan-Cancer Panel
Targeting 1385 cancer genes for gene expression, variant, and fusion detection studies in many RNA sample types including blood, bone marrow, and formalin-fixed, paraffin-embedded (FFPE) tissue.
TruSight Oncology Product Family
Solutions to enable comprehensive genomic profiling, from tissue to liquid biopsy samples.
TruSight Oncology 500 Portfolio
Assays designed to identify relevant biomarkers in guidelines and clinical research, such as tumor mutational burden (TMB) and microsatellite instability (MSI).
TruSight Tumor 170
Comprehensive panel detects single-nucleotide variants (SNVs), amplifications, and fusions that contribute to solid tumor progression.
TruSight RNA Fusion
Targeting 507 fusion associated genes in cancer; detects known and novel fusion gene partners.
TruSight RNA Pan-Cancer
Targeting 1385 oncology genes for gene expression, variant and fusion detection in all RNA sample types including FFPE.
TruSight Myeloid
Uses expert-defined content to identify somatic mutations in myeloid malignancies.
TruSight Hereditary Cancer Panel
Expert-defined content targeting 113 genes associated with genetic cancer risk predisposition.
TruSight Cancer
Sequencing research panels targeting 94 genes and 284 SNPs associated with a predisposition towards various cancers.
TruSight Tumor 15
Focused panel that assesses common somatic variants in solid tumors.
TruSight One Sequencing Panels
Comprehensive panels targeting disease-associated regions of the exome with high analytical sensitivity and specificity.
TruSight Cardio
A comprehensive, cost-effective solution for identifying causal variants implicated in inherited cardiac conditions.
Discontinued TruSight products and recommended replacements:
- The TruSight Inherited Disease Sequencing Panel has been discontinued. Illumina DNA Prep with Enrichment is the recommended library prep and enrichment replacement.
- The TruSight Cardiomyopathy Sequencing Panel has been discontinued. TruSight Cardio is the recommended replacement.
- The TruSight Autism Sequencing Panel has been discontinued. Content from this panel is available in the comprehensive TruSight One Sequencing Panel.
- The TruSight HLA v2 Sequencing Panel is now available from CareDx instead of Illumina. Visit the CareDx TruSight HLA page for ordering and technical support.
- TruSight Lymphoma 40 panels (20015966 - 8 samples and 20015967 - 48 samples) have been discontinued. Contact your Illumina Sales Account Manager or Illumina Clinical Specialist to identify the best plan of action to support your gene panel needs.